

CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

View Online



Azarova, A.M., Gautam, G. and George, R.E. (2011) 'Emerging importance of ALK in neuroblastoma', *Seminars in Cancer Biology*, 21(4), pp. 267–275. Available at: <https://doi.org/10.1016/j.semcancer.2011.09.005>.

Beierle, E.A. (no date) 'MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)', *Frontiers in bioscience (Elite edition)*, 3. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>.

Bell, E. et al. (2010) 'MYCN oncoprotein targets and their therapeutic potential', *Cancer Letters*, 293(2), pp. 144–157. Available at: <https://doi.org/10.1016/j.canlet.2010.01.015>.

Bender, S. et al. (2013) 'Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas', *Cancer Cell*, 24(5), pp. 660–672. Available at: <https://doi.org/10.1016/j.ccr.2013.10.006>.

Berry, T. et al. (2012) 'The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma', *Cancer Cell*, 22(1), pp. 117–130. Available at: <https://doi.org/10.1016/j.ccr.2012.06.001>.

Bleggi-Torres, L.F. et al. (2001) 'Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system', *Diagnostic Cytopathology*, 24(4), pp. 293–295. Available at: <https://doi.org/10.1002/dc.1062>.

Blümcke, I. et al. (2016) 'Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification', *Nature Reviews Neurology*, 12(12), pp. 732–740. Available at: <https://doi.org/10.1038/nrneurol.2016.173>.

Brodeur, G.M. (2003) 'Neuroblastoma: biological insights into a clinical enigma', *Nature Reviews Cancer*, 3(3), pp. 203–216. Available at: <https://doi.org/10.1038/nrc1014>.

Brodeur, G.M. and Bagatell, R. (2014) 'Mechanisms of neuroblastoma regression', *Nature Reviews Clinical Oncology*, 11(12), pp. 704–713. Available at: <https://doi.org/10.1038/nrclinonc.2014.168>.

Brown, C.E. et al. (2016) 'Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy', *New England Journal of Medicine*, 375(26), pp. 2561–2569. Available at: <https://doi.org/10.1056/NEJMoa1610497>.

Buckner, T., Blatt, J. and Smith, S.V. (2006) 'The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience', *Pediatric and Developmental Pathology*, 9(5),

pp. 374–380. Available at: <https://doi.org/10.2350/06-02-0047.1>.

Burkhart, C.A. et al. (2003) 'Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma', *JNCI Journal of the National Cancer Institute*, 95(18), pp. 1394–1403. Available at: <https://doi.org/10.1093/jnci/djg045>.

Chen, L. et al. (2010) 'p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma', *Cancer Research*, 70(4), pp. 1377–1388. Available at: <https://doi.org/10.1158/0008-5472.CAN-09-2598>.

Chhabda, S. et al. (2016) 'The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know', *Quantitative Imaging in Medicine and Surgery*, 6(5), pp. 486–489. Available at: <https://doi.org/10.21037/qims.2016.10.01>.

Children's cancer statistics | Cancer Research UK (no date). Available at: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>.

Cossu, I. et al. (2015) 'Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion', *Biomaterials*, 68, pp. 89–99. Available at: <https://doi.org/10.1016/j.biomaterials.2015.07.054>.

Ellison, D.W. et al. (2005) 'β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee', *Journal of Clinical Oncology*, 23(31), pp. 7951–7957. Available at: <https://doi.org/10.1200/JCO.2005.01.5479>.

Evans, A.E., Baum, E. and Chard, R. (1981) 'Do infants with stage IV-S neuroblastoma need treatment?', *Archives of Disease in Childhood*, 56(4), pp. 271–274. Available at: <https://doi.org/10.1136/adc.56.4.271>.

Fisher, J. et al. (2017) 'Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor', *Molecular Therapy*, 25(5), pp. 1234–1247. Available at: <https://doi.org/10.1016/j.ymthe.2017.03.002>.

Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop (1984) 'Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage', *Science*, 224(4653), pp. 1121–1124. Available at: <http://www.jstor.org/stable/1692440>.

Ghorashian, S., Amrolia, P. and Veys, P. (2018) 'Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL', *Experimental Hematology*, 66, pp. 5–16. Available at: <https://doi.org/10.1016/j.exphem.2018.07.002>.

Gibson, P. et al. (2010) 'Subtypes of medulloblastoma have distinct developmental origins', *Nature*, 468(7327), pp. 1095–1099. Available at: <https://doi.org/10.1038/nature09587>.

Goschzik, T. et al. (2017) 'Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma', *Journal of Neuropathology & Experimental Neurology* [Preprint]. Available at: <https://doi.org/10.1093/jnen/nlw116>.

- Greaves, M.F. and Wiemels, J. (2003) 'Origins of chromosome translocations in childhood leukaemia', *Nature Reviews Cancer*, 3(9), pp. 639–649. Available at: <https://doi.org/10.1038/nrc1164>.
- Guglielmi, L. et al. (2014) 'MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells', *Cell Death & Disease*, 5(2), pp. e1081–e1081. Available at: <https://doi.org/10.1038/cddis.2014.42>.
- Gump, J.M. et al. (2015) 'Identification of targets for rational pharmacological therapy in childhood craniopharyngioma', *Acta Neuropathologica Communications*, 3(1). Available at: <https://doi.org/10.1186/s40478-015-0211-5>.
- Hanahan, D. and Weinberg, R.A. (2000) 'The Hallmarks of Cancer', *Cell*, 100(1), pp. 57–70. Available at: [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9).
- Hanahan, D. and Weinberg, R.A. (2011) 'Hallmarks of Cancer: The Next Generation', *Cell*, 144(5), pp. 646–674. Available at: <https://doi.org/10.1016/j.cell.2011.02.013>.
- Hashizume, R. et al. (2014) 'Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma', *Nature Medicine*, 20(12), pp. 1394–1396. Available at: <https://doi.org/10.1038/nm.3716>.
- Hasle, H. and Niemeyer, C.M. (2011) 'Advances in the prognostication and management of advanced MDS in children', *British Journal of Haematology*, 154(2), pp. 185–195. Available at: <https://doi.org/10.1111/j.1365-2141.2011.08724.x>.
- Hill, R.M. et al. (2015) 'Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease', *Cancer Cell*, 27(1), pp. 72–84. Available at: <https://doi.org/10.1016/j.ccell.2014.11.002>.
- Hourigan, C.S. and Karp, J.E. (2013) 'Minimal residual disease in acute myeloid leukaemia', *Nature Reviews Clinical Oncology*, 10(8), pp. 460–471. Available at: <https://doi.org/10.1038/nrclinonc.2013.100>.
- Huang, M. and Weiss, W.A. (2013) 'Neuroblastoma and MYCN', *Cold Spring Harbor Perspectives in Medicine*, 3(10), pp. a014415–a014415. Available at: <https://doi.org/10.1101/cshperspect.a014415>.
- Huber, K., Kalcheim, C. and Unsicker, K. (2009) 'The development of the chromaffin cell lineage from the neural crest', *Autonomic Neuroscience*, 151(1), pp. 10–16. Available at: <https://doi.org/10.1016/j.autneu.2009.07.020>.
- Hubert, C.G. et al. (2016) 'A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found', *Cancer Research*, 76(8), pp. 2465–2477. Available at: <https://doi.org/10.1158/0008-5472.CAN-15-2402>.
- Hunger, S.P. and Mullighan, C.G. (2015) 'Acute Lymphoblastic Leukemia in Children', *New England Journal of Medicine*, 373(16), pp. 1541–1552. Available at: <https://doi.org/10.1056/NEJMra1400972>.

International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. Revised 4th edition. Edited by D.N. Louis et al. Lyon: International Agency for Research on Cancer.

Johnson, L.A. and June, C.H. (2017) 'Driving gene-engineered T cell immunotherapy of cancer', *Cell Research*, 27(1), pp. 38–58. Available at: <https://doi.org/10.1038/cr.2016.154>.

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola (1998) 'Autopsy in children with cancer who die while in terminal care', *Medical and Pediatric Oncology*, 30(5), pp. 284–289. Available at: [https://doi.org/10.1002/\(SICI\)1096-911X\(199805\)30:5<284::AID-MPO4>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B).

Klebanoff, C.A., Rosenberg, S.A. and Restifo, N.P. (2016) 'Prospects for gene-engineered T cell immunotherapy for solid cancers', *Nature Medicine*, 22(1), pp. 26–36. Available at: <https://doi.org/10.1038/nm.4015>.

Koebel, C.M. et al. (2007) 'Adaptive immunity maintains occult cancer in an equilibrium state', *Nature*, 450(7171), pp. 903–907. Available at: <https://doi.org/10.1038/nature06309>.

Korshunov, Andrey Sturm, Dominik Ryzhova, Marina Hovestadt, Volker Gessi, Marco (no date) 'Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity', *Acta Neuropathologica*, 128(8), pp. 279–89. Available at: <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>.

Kotrova, M. et al. (2017) 'Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?', *Molecular Diagnosis & Therapy*, 21(5), pp. 481–492. Available at: <https://doi.org/10.1007/s40291-017-0277-9>.

Larson, J.D. et al. (2018) 'Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression', *Cancer Cell* [Preprint]. Available at: <https://doi.org/10.1016/j.ccell.2018.11.015>.

Lee, T.I. and Young, R.A. (2013) 'Transcriptional Regulation and Its Misregulation in Disease', *Cell*, 152(6), pp. 1237–1251. Available at: <https://doi.org/10.1016/j.cell.2013.02.014>.

Lewis, P.W. et al. (2013) 'Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma', *Science*, 340(6134), pp. 857–861. Available at: <https://doi.org/10.1126/science.1232245>.

Liu, Z. and Thiele, C.J. (2012) 'ALK and MYCN: When Two Oncogenes Are Better than One', *Cancer Cell*, 21(3), pp. 325–326. Available at: <https://doi.org/10.1016/j.ccr.2012.03.004>.

Lord, C.J. and Ashworth, A. (2010) 'Biology-driven cancer drug development: back to the future', *BMC Biology*, 8(1). Available at: <https://doi.org/10.1186/1741-7007-8-38>.

Lu, B. et al. (2016) 'Wnt Drug Discovery: Weaving Through the Screens, Patents and

Clinical Trials', *Cancers*, 8(9). Available at: <https://doi.org/10.3390/cancers8090082>.

Mackall, C.L., Merchant, M.S. and Fry, T.J. (2014) 'Immune-based therapies for childhood cancer', *Nature Reviews Clinical Oncology*, 11(12), pp. 693–703. Available at: <https://doi.org/10.1038/nrclinonc.2014.177>.

Majzner, R.G., Heitzeneder, S. and Mackall, C.L. (2017) 'Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers', *Cancer Cell*, 31(4), pp. 476–485. Available at: <https://doi.org/10.1016/j.ccell.2017.03.002>.

Marabelle, A. et al. (2009) 'Hypercalcemia and 13-*cis*-retinoic acid in post-consolidation therapy of neuroblastoma', *Pediatric Blood & Cancer*, 52(2), pp. 280–283. Available at: <https://doi.org/10.1002/pbc.21768>.

Martinez-Barbera, J.P. and Andoniadou, C.L. (2016) 'Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma', *STEM CELLS*, 34(2), pp. 268–276. Available at: <https://doi.org/10.1002/stem.2267>.

Martinez-Barbera, J.P. and Buslei, R. (2015) 'Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models', *Journal of Pediatric Endocrinology and Metabolism*, 28(1–2). Available at: <https://doi.org/10.1515/jpem-2014-0442>.

Matthay, K.K. et al. (1999) 'Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-*cis*-Retinoic Acid', *New England Journal of Medicine*, 341(16), pp. 1165–1173. Available at: <https://doi.org/10.1056/NEJM199910143411601>.

Milne, T.A. (2017) 'Mouse models of MLL leukemia: recapitulating the human disease', *Blood*, 129(16), pp. 2217–2223. Available at: <https://doi.org/10.1182/blood-2016-10-691428>.

Morsut, L. et al. (2016) 'Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors', *Cell*, 164(4), pp. 780–791. Available at: <https://doi.org/10.1016/j.cell.2016.01.012>.

Mossé, Y.P. et al. (2008) 'Identification of ALK as a major familial neuroblastoma predisposition gene', *Nature*, 455(7215), pp. 930–935. Available at: <https://doi.org/10.1038/nature07261>.

Nataliya Zhukova (2013) 'Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma', *Journal of Clinical Oncology*, 31(23). Available at: <https://doi.org/10.1200/JCO.2012.48.5052>.

'Nature Reviews Immunology' (2012), 12(4). Available at: <https://www.nature.com/nri/volumes/12/issues/4>.

Niemeyer, C.M. and Kratz, C.P. (2008) 'Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options', *British Journal of Haematology*, 140(6), pp. 610–624. Available at: <https://doi.org/10.1111/j.1365-2141.2007.06958.x>.

- Niklison-Chirou, M.V. et al. (2017) 'TAp73 is a marker of glutamine addiction in medulloblastoma', *Genes & Development*, 31(17), pp. 1738–1753. Available at: <https://doi.org/10.1101/gad.302349.117>.
- Northcott, P.A. et al. (2012) 'The clinical implications of medulloblastoma subgroups', *Nature Reviews Neurology*, 8(6), pp. 340–351. Available at: <https://doi.org/10.1038/nrneurol.2012.78>.
- O'Connor, D. et al. (2018a) 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia', *Journal of Clinical Oncology*, 36(1), pp. 34–43. Available at: <https://doi.org/10.1200/JCO.2017.74.0449>.
- O'Connor, D. et al. (2018b) 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia', *Journal of Clinical Oncology*, 36(1), pp. 34–43. Available at: <https://doi.org/10.1200/JCO.2017.74.0449>.
- Pastorino, F. et al. (2007) 'Ligand-Targeted Liposomal Therapies of Neuroblastoma', *Current Medicinal Chemistry*, 14(29), pp. 3070–3078. Available at: <https://doi.org/10.2174/092986707782793916>.
- Pathania, M. et al. (2017) 'H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas', *Cancer Cell*, 32(5), pp. 684–700.e9. Available at: <https://doi.org/10.1016/j.ccell.2017.09.014>.
- Pfister, S. et al. (2009) 'Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes', *Acta Neuropathologica*, 117(4), pp. 457–464. Available at: <https://doi.org/10.1007/s00401-008-0467-y>.
- Phoenix, T.N. et al. (2016) 'Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype', *Cancer Cell*, 29(4), pp. 508–522. Available at: <https://doi.org/10.1016/j.ccell.2016.03.002>.
- Qasim, W. et al. (2017) 'Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells', *Science Translational Medicine*, 9(374). Available at: <https://doi.org/10.1126/scitranslmed.aaj2013>.
- Qiao, J. et al. (2012) 'PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation', *Biochemical and Biophysical Research Communications*, 424(3), pp. 421–426. Available at: <https://doi.org/10.1016/j.bbrc.2012.06.125>.
- Rasaiyaah, J. et al. (2018) 'TCR $\alpha\beta$ /CD3 disruption enables CD3-specific antileukemic T cell immunotherapy', *JCI Insight*, 3(13). Available at: <https://doi.org/10.1172/jci.insight.99442>.
- Reynolds, C.P. et al. (2003) 'Retinoid therapy of high-risk neuroblastoma', *Cancer Letters*, 197(1–2), pp. 185–192. Available at: [https://doi.org/10.1016/S0304-3835\(03\)00108-3](https://doi.org/10.1016/S0304-3835(03)00108-3).
- Richmond, A. and Su, Y. (2008) 'Mouse xenograft models vs GEM models for human cancer therapeutics', *Disease Models and Mechanisms*, 1(2–3), pp. 78–82. Available at: <https://doi.org/10.1242/dmm.000976>.
- Sadelain, M., Rivière, I. and Riddell, S. (2017) 'Therapeutic T cell engineering', *Nature*,

545(7655), pp. 423–431. Available at: <https://doi.org/10.1038/nature22395>.

Schwab, M. (2004) 'MYCN in neuronal tumours', *Cancer Letters*, 204(2), pp. 179–187. Available at: [https://doi.org/10.1016/S0304-3835\(03\)00454-3](https://doi.org/10.1016/S0304-3835(03)00454-3).

Schwalbe, E.C. et al. (2017) 'Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study', *The Lancet Oncology*, 18(7), pp. 958–971. Available at: [https://doi.org/10.1016/S1470-2045\(17\)30243-7](https://doi.org/10.1016/S1470-2045(17)30243-7).

Schwalbe, Ed.C. et al. (2013) 'Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types', *Acta Neuropathologica*, 126(6), pp. 943–946. Available at: <https://doi.org/10.1007/s00401-013-1206-6>.

Schwartzentruber, J. et al. (2012) 'Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma', *Nature*, 482(7384), pp. 226–231. Available at: <https://doi.org/10.1038/nature10833>.

Sidell, N. (1982) 'Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro', *JNCI: Journal of the National Cancer Institute* [Preprint]. Available at: <https://doi.org/10.1093/jnci/68.4.589>.

Slany, R.K. (2016) 'The molecular mechanics of mixed lineage leukemia', *Oncogene*, 35(40), pp. 5215–5223. Available at: <https://doi.org/10.1038/onc.2016.30>.

Stone, T.J. and Jacques, T.S. (2015) 'Medulloblastoma: selecting children for reduced treatment', *Neuropathology and Applied Neurobiology*, 41(2), pp. 106–108. Available at: <https://doi.org/10.1111/nan.12193>.

Strebhardt, K. and Ullrich, A. (2008) 'Paul Ehrlich's magic bullet concept: 100 years of progress', *Nature Reviews Cancer*, 8(6), pp. 473–480. Available at: <https://doi.org/10.1038/nrc2394>.

Sturm, D. et al. (2012) 'Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma', *Cancer Cell*, 22(4), pp. 425–437. Available at: <https://doi.org/10.1016/j.ccr.2012.08.024>.

Sturm, D. et al. (2016) 'New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs', *Cell*, 164(5), pp. 1060–1072. Available at: <https://doi.org/10.1016/j.cell.2016.01.015>.

Taylor, Michael D Northcott, Paul A Korshunov, Andrey Remke, Marc Cho, Yoon-jae (no date) 'Molecular subgroups of medulloblastoma: the current consensus', *Acta Neuropathologica*, 123(3), pp. 465–72. Available at: https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo.

Vogelstein, B. et al. (2013a) 'Cancer Genome Landscapes', *Science*, 339(6127), pp. 1546–1558. Available at: <https://doi.org/10.1126/science.1235122>.

Vogelstein, B. et al. (2013b) 'Cancer Genome Landscapes', *Science*, 339(6127), pp. 1546–1558. Available at: <https://doi.org/10.1126/science.1235122>.

Vora, A. et al. (2013) 'Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial', *The Lancet Oncology*, 14(3), pp. 199–209. Available at: [https://doi.org/10.1016/S1470-2045\(12\)70600-9](https://doi.org/10.1016/S1470-2045(12)70600-9).

Vora, A. et al. (2014) 'Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial', *The Lancet Oncology*, 15(8), pp. 809–818. Available at: [https://doi.org/10.1016/S1470-2045\(14\)70243-8](https://doi.org/10.1016/S1470-2045(14)70243-8).

Wegman-Ostrosky, T. and Savage, S.A. (2017) 'The genomics of inherited bone marrow failure: from mechanism to the clinic', *British Journal of Haematology*, 177(4), pp. 526–542. Available at: <https://doi.org/10.1111/bjh.14535>.

Weinberg, R.A. (2014) *The biology of cancer*. 2nd ed. New York: Garland Science.

Wright, J.H. (1910) 'NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED', *The Journal of Experimental Medicine*, 12(4). Available at: <https://doi.org/10.1084/jem.12.4.556>.

Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing (no date) 'PHOX2B Is Associated with Neuroblastoma Cell Differentiation', *Cancer Biotherapy & Radiopharmaceuticals*, 31, pp. 44–51. Available at: <https://doi.org/10.1089/cbr.2015.1952>.

Yong, C.S.M. et al. (2017) 'CAR T-cell therapy of solid tumors', *Immunology and Cell Biology*, 95(4), pp. 356–363. Available at: <https://doi.org/10.1038/icb.2016.128>.

Zelent, A., Greaves, M. and Enver, T. (2004) 'Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia', *Oncogene*, 23(24), pp. 4275–4283. Available at: <https://doi.org/10.1038/sj.onc.1207672>.

Zhu, S. et al. (2012) 'Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis', *Cancer Cell*, 21(3), pp. 362–373. Available at: <https://doi.org/10.1016/j.ccr.2012.02.010>.